NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.
| Revenue (Most Recent Fiscal Year) | $99.99M |
| Net Income (Most Recent Fiscal Year) | $-27.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.58 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 23.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -21.47% |
| Net Margin (Trailing 12 Months) | -21.47% |
| Return on Equity (Trailing 12 Months) | -105.67% |
| Return on Assets (Trailing 12 Months) | -20.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.09 |
| Inventory Turnover (Trailing 12 Months) | 1.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.66 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 33.67M |
| Free Float | 26.77M |
| Market Capitalization | $457.87M |
| Average Volume (Last 20 Days) | 0.19M |
| Beta (Past 60 Months) | 1.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |